一、基本信息

练炼，男，1981年10月出生，医学博士，副主任医师，硕士生导师，苏州市相城人民医院科教科科长，邮箱：dr_lianlian@163.com。

二、教育经历

1999.9—2004.7，南京医科大学，第一临床医学院，临床医学专业，学士

2007.9—2010.7，苏州大学，附属第一医院，肿瘤学专业，硕士

2003.9—2006.7，苏州大学，附属第一医院，肿瘤学专业，博士

三、研究方向

1、肿瘤基因组学指导下的个体化治疗研究

2、晚期胃癌的基础与临床研究

3、仿生纳米载药体系在肿瘤诊疗中的应用与研究

四、承担项目

1、苏州市民生科技项目，关键技术应用研究（编号SS202093）“基于金属硫化物的仿生复合纳米材料在非小细胞肺癌靶向放疗增敏中的技术应用研究”，2020/7—2023/6，10万，主持

2、苏州市民生科技项目，关键技术应用研究（编号SS201852）“二甲双胍和沙利度胺共载iRGD修饰的纳米靶向投递系统对改善食管癌乏氧微环境的作用及机制研究”，2018/7—2021/6，10万，主持

3、苏州市相城区科技项目（编号XWKJ201702）“VEGFR2通过调控VTN促进胃癌生长转移的作用及分子机制研究”，2017/7—2019/6，5万，主持

4、苏州市相城区科技项目（编号XJ201642）“基于VEGFR2/PP2A/AKT信号轴远端胃癌精准治疗的机制研究”，2016/7—2018/6，5万，主持

5、苏州市科技项目（面上项目，编号SYS201504）“基于SATB1基因的非小细胞肺癌驱动机制及治疗价值研究”，2015/7—2018/6，3万，主持

6、苏州市相城区科技项目（编号XJ201538）“基于药物基因组学分子标志的晚期胃癌患者铂类化疗药物的疗效及预后预测研究”，2015/7—2017/6，5万，主持

7、苏州市相城区科技项目（编号XJ20145）“乳腺癌循环肿瘤细胞上皮间质转化调节蛋白FOXC1的表达及意义”，2014/7—2017/6，4万，主持

8、苏州市相城区科技项目（编号SZXC2012-70）“DPDmRNA及TSmRNA表达水平指导下含替吉奥的方案在进展期胃癌患者个体化治疗中的研究”，2012/7—2015/6，8万，主持

五、代表性论著

1.Wang X, Shi Q, Zha Z, Zhu D, Zheng L, Shi L, Wei X,Lian L（练炼）, Wu K, Cheng L.Copper single-atom catalysts with photothermal performance and enhanced nanozyme activity for bacteria-infected wound therapy[J].Bioactive Materials,2021, 6( 12), 4389-4401.

2.Yi H, Liao ZW, Chen JJ, Shi XY, ChenGL, Wu GT, Zhou DY, Zhou GQ, Huang JY,Lian L*（练炼）, Yu ZY*,He SB*. Genome variation in colorectal cancer patient with liver metastasis measured by whole-exome sequencing[J].Journal of Gastrointestinal Oncology, 2021, 12(2):507-515.

3.Qiu X, Tan G, Wen H,Lian L*（练炼）,Xiao S*. Forkhead box O1 targeting replication factor C subunit2 expression promotes glioma temozolomide resistance andsurvival[J].Ann Transl Med,2021;9(8):692. doi: 10.21037/atm-21-1523

4.Yu-Jie Lu#,Lian Lian#（练炼）, Xiao-Ming Shen#, Ying Li, Sheng-Jun Ji, Wen-Jie Wang, Yi Yang,Ying Wang, Wei-Ming Duan A bioinformatics analysis to evaluate the prognostic value of stemness-related genes in gastric cancer[J].Transl Cancer Res2021, 10(1):174-183.

5.Zhou C, Xia Y, Huang P, Guan L, Shen X, Hao D, Chen M, Ren H,Lian L*（练炼）, and Yin H*. Fractionated Stereotactic Radiation Therapy Using Volumetric Modulated Arc Therapy in Patients with Solitary Brain Metastases [J].Biomed Res Int, 2020:6342057.

6.Lu YJ, Cui MT, Liang ZW, Wang WJ, Jiang M, Xu MD, Wu MY, Shen M, Li W, Gao Y*,Lian L*（练炼）, Duan WM*. Prognostic values of platelet-associated indicators in advanced breast cancer[J].Transl Cancer Res2019;8(4):1326-1335.

7.Lian L#（练炼）, Li XL#, Xu MD#,Li XM, Wu MY, Zhang Y, Tao M, Li W , Shen XM, Zhou C, Jiang M.VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer[J].BMC Cancer, 2019, 19(1):183.

8.YouY Xia#, ChenX Hu#,Lian L#（练炼）,KaiY Hui,Lei Wang,Yun Qiao,Liang Liu,LiJ Liang,XiaoD Jiang. miR497 suppresses malignant phenotype in nonsmall cell lung cancer via targeting KDR[J].Oncol Rep.2019;42(1): 443-452

9.Zhu J# ,Lian L#（练炼）, Qin H , et al. Prognostic evaluation of patients with resectable lung cancer using systemic inflammatory response parameters[J].Oncology letters, 2019, 17 (2)2244-2256

10.Shen XM#, Xia YY#,Lian L#（练炼）, Zhou C,Li XL, Han SG, Zheng Y,Mao ZQ, Gong FR,, Tao M,Mao ZQ*,Li W*Mean platelet volume provides beneficial diagnostic and prognostic information for patients with resectable gastric cancer.Oncol Lett,2016, 12(4):2501 -2506.

11.Lian L#（练炼）, Xia YY#, Zhou C, Shen XM, Li XL, Han SG, Zheng Y, Mao ZQ, Gong FR, Wu MY, Chen K, Tao M*, Li W* Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.Cancer biomark2015;15（6）:899-907

12.Lian L#（练炼）, Xia YY#, Zhou C, Shen XM, Li XL, Han SG, Zheng Y, Gong FR, Tao M*, Li W*.Mean platelet volume predicts chemotherapy response and prognosis in patients with unresectable gastric cancer.Oncol Lett2015;(10): 3419-3424

13.Wang F, Lui ZY, Xia YY, Zhou C, Shen XM, Li XL, Han SG, Zheng Y, Mao ZQ,Gong FR, Tao M,Lian L*（练炼）, Li W*.Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer.Oncol Lett2015;(10): 3411-3418

14.Lian L（练炼）, Li W*, Li ZY, Mao YX, Zhang YT, Zhao YM, Chen K, Duan WM, Tao M*. Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs.Oncol Lett2013; 5:675-80.

15.Li W, Liang RR, Zhou C, Wu MY,Lian L（练炼）, Yuan GF, Wang MY, Xie X, Shou LM, Gong FR, Chen K, Duan WM, Tao M*.The association between expressions of Ras and CD68 in the angiogenesis of breast cancers.Cancer Cell Int.2015;(1): 17.

16.Shen M, Duan WM, Wu MY, Wang WJ, Liu L,Xu M D,Zhu J,Li DM,Gui Q,Lian L（练炼）,Gong FR,Chen K,Li W*, Tao M*. Participation of autophagy in the cytotoxicity against breast cancer cells by cisplatin.Oncol Rep.2015;34(1): 359-367.

17.Wu MY,Liang RR,Chen K,Shen M,Tian Y.L,Li DM,Duan WM,Gui Q,Gong F R,Lian L（练炼）,Li W*,Tao M*. FH535 inhibited metastasis and growth of pancreatic cancer cells.Onco Targets Ther2015;(8): 1651-1670.

18.Shen XM, Zhou C,Lian L（练炼）, Li LQ, Li W*, Tao M*. Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer.Cell Biochem Biophys.2015;71(3):1653-1661

19.Shou LM, Zhang QY, Li W*, Xie X, Chen K,Lian L（练炼）, Li ZY, Gong FR, Dai KS, Mao YX, Tao M*. Cantharidin and norcantharidin inhibit the ability of MCF-7 cells to adhere to platelets via protein kinase C pathway-dependent downregulation of alpha2 integrin.Oncol Rep2013; 30(3):1059-66.

20.韩曙光,慎晓明,周冲,李伟,陶敏,练炼*血小板/淋巴细胞比率和中性粒细胞/淋巴细胞比率对胃癌早期诊断和预后的预测价值研究[J].临床医药文献电子杂志, 2019年6卷49期, 4-6页, 2019.（通讯作者）

21.李先敏,练炼,慎晓明.外周血中DPD mRNA和TS mRNA表达对含卡培他滨方案治疗进展期胃癌的疗效预测[J].江苏大学学报（医学版）, 2019, 29(3):264-268.

22.练炼,慎晓明,周冲,陶敏.胃癌患者血清DPDmRNA和TSmRNA表达对替吉奥疗效预测价值分析[J].中华肿瘤防治杂志,2015,22(5);368-372

23.练炼,李伟,张有涛,赵益明,陶敏.MCF-7细胞诱导血小板聚集机制研究[J].中华肿瘤防治杂志,2014,21(8);589-593

24.练炼,慎晓明,周冲,李伟,陶敏.DPDmRNA及TSmRNA表达与进展期胃癌患者含替吉奥方案的化疗临床预后的关系.海南医学,2015,26(6);799-802

六、获奖情况

1. 2016年苏州市相城区自然科学优秀学术论文二等奖；

2.2017年苏州市相城区四创青年；

3.2019年苏州市阳澄湖医卫人才青年拔尖人才；

4.2020年苏州市医学新技术二等奖（XJS2020072，排名第一）。